Endonovo Therape Stock Price, News & Analysis

Endonovo Therapeutics, Inc. (OTCQB:ENDV) has appointed NAMSA as strategic advisors to enhance reimbursement strategies for its SofPulse^® product. The collaboration aims to accelerate reimbursement and commercialization efforts, leveraging NAMSA's extensive experience in medical device reimbursement across global markets. NAMSA, a leading Contract Research Organization, will aid Endonovo in navigating complex reimbursement landscapes to facilitate market access for SofPulse^®, which is FDA-cleared and CE marked for various therapeutic applications.

Endonovo Therapeutics (OTCQB: ENDV) has initiated a $5 million Regulation A+ common stock offering to advance medical reimbursements for its SofPulse® devices. Extensive market research indicates that achieving reimbursement could significantly enhance the device's availability in U.S. hospitals, where it's proposed as a standard of care for surgical pain and edema management. Clinical studies document impressive efficacy, such as a 2.2X reduction in postoperative narcotic use. Current studies at Columbia and Stanford could facilitate reimbursement applications.

Endonovo Therapeutics (OTC-ENDV) has appointed Garry Michael Kann as the Head of Corporate Development to spearhead the company's new strategy for acquiring specialty service providers in the construction industry. Mr. Kann brings over 30 years of experience in corporate finance and M&A, having completed numerous transactions worth over $2 billion. His goal is to find high-margin subcontractors that will enhance Endonovo's revenue and profit margins. CEO Alan Collier expressed confidence in Kann’s capabilities to execute this strategy, which aims to deliver long-term shareholder value.

Endonovo Therapeutics (OTC-ENDV) announced the filing of a Regulation A+ financing to expand its operations, repaying its senior secured Note, and funding research and development. The company has partnered with Dalmore Group, a leading broker-dealer specializing in Reg A+, to facilitate this financing. Dalmore's extensive experience and established relationships in the market position Endonovo favorably for its capital raising needs. CEO Alan Collier expressed optimism about the collaboration with Dalmore, highlighting the advantages of Reg A+ offerings for minimizing shareholder dilution.

Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced on October 12, 2021, progress on its "Build Up Strategy" aimed at acquiring complementary companies in the construction sector. The first Letter of Intent was signed on July 29, 2021, to acquire a business with a 17% annual growth rate and projected revenues of $20 million in 2021. The acquisition is expected to close by December 31, 2021, and the company aims to enhance its medical device offerings alongside this new venture. Endonovo's core product, the SofPulse^® device, continues to gain traction in pain management, with ongoing clinical trials.

Endonovo Therapeutics (ENDV) announced the shipment of its SofPulse® tPEMF devices for a Stanford University study on post-operative pain management. The study aims to evaluate the efficacy of SofPulse® in reducing pain and narcotic usage after orthopedic surgeries, concluding in August 2022. Previous studies, including one at Baylor College of Medicine, showed significant reductions in pain and opioid requirements. Endonovo's CEO expressed optimism about the collaboration's potential to position SofPulse® as a standard pain management solution in orthopedic procedures.

Endonovo Therapeutics (OTCQB: ENDV) has launched a new marketing campaign for its FDA-cleared SofPulse® device, which aims to mitigate opioid use post-surgery, exacerbated by COVID-19. With data showing a 70% reduction in opioid requirements and a 50% decrease in post-operative pain, the device has shown its potential in clinical trials. Alan Collier, CEO, emphasizes the device's role in public health by potentially saving lives and reducing hospital costs. The company projects SofPulse® could save hospitals over $5.7 billion annually if adopted broadly in surgeries.